PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsNeuroendocrine tumors
MeSH D018358 - neuroendocrine tumors
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D017599:Neuroectodermal tumors
0 Companies
0 Drugs
Success rate
D018358: 
Neuroendocrine tumors
$
Success rate
D000237:Basophil adenoma
0 Companies
0 Drugs
Success rate
D000238:Chromophobe adenoma
0 Companies
0 Drugs
Success rate
D000239:Acidophil adenoma
0 Companies
0 Drugs
Success rate
D001079:Apudoma
0 Companies
0 Drugs
Success rate
D002276:Carcinoid tumor
$
Success rate
D008545:Melanoma
D009442:Neurilemmoma
0 Companies
0 Drugs
Success rate
D010235:Paraganglioma
0 Companies
0 Drugs
Success rate
D018278:Neuroendocrine carcinoma
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Accord HealthcareSunitinib Sunitinib Accord  2021-02-11   
Advanced Accelerator ApplicationsLutetium (177lu) oxodotreotide, Lutetium lu 177 dotatate Lutathera  2017-09-26   
Edotreotide SomaKit TOC  2016-12-08   
CiplaLanreotide Lanreotide  2021-12-17   
CP Pharmaceuticals International CVSunitinib Sutent  2006-01-26   
Dr Reddys LaboratoriesSunitinib Sunitinib  2022-04-11   
Eugia Pharma SpecialtiesSunitinib Sunitinib  2024-03-14   
IpsenLanreotide Somatuline Depot  2007-08-30   
Merck Sharp & DohmeAvelumab Bavencio  2017-09-18   
MylanSunitinib Sunitinib  2021-12-06   
NATCO PharmaSunitinib Sunitinib  2023-10-24   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
74%
40/54
Phase 2
34%
30/89
Phase 3
25%
9/36
Approved: 5Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Advanced Accelerator Applications
Ipsen
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use